Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | ALPL | P05186 | 2/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6972429 | 0.84 | ALPL (0.47) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL10646541 | 0.82 | SLC22A12 (0.48) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL29469931 | 0.82 | PTGES2 (0.55) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL29520001 | 0.82 | SLC22A12 (0.48) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL645001 | 0.82 | ALPL (0.46) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL6039108 | 0.82 | SLC22A12 (0.48) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL2646108 | 0.82 | ALPL (0.46) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL692280 | 0.82 | PTGES2 (0.55) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| SCHEMBL122293 | 0.82 | SLC22A12 (0.48) | ELANEALPLSLC22A12SLC40A1PTGES2 | |
| Hydrochloric Acid SCHEMBL4436765 | 0.81 | PTGES2 (0.53) | ELANEALPLSLC22A12SLC40A1PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642272-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1611090-A2 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085385-A2 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040186148-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186148-A1 | Cannabinoid receptor ligands | CNR1, CNR2, TRPV1 | ELANE 1597/4885ALPL 2938/4885SLC22A12 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.